Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2024-08-27 00:00:00 ET · period of report 2024-08-27 · accession 0001415889-24-022363 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-27 | 2024-08-27 | HALO | LaBarre Michael J. | SVP, Chief TECHNICAL Off | M - OptEx | $18.41 | +5,580 | 173.8K | +3% | +$102.7K |
| D | 2024-08-27 | 2024-08-27 | HALO | LaBarre Michael J. | SVP, Chief TECHNICAL Off | M - OptEx | $0.00 | -5,580 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-27 | M | A | 5,580 | $18.41 | 173,756 | D | — | — | |
| 2 | Derivative | Option to Purchase Common Stock | 2024-08-27 | M | D | 5,580 | $0.00 | 0 | D | $18.41 · — to 2028-02-14 | 5,580 Common Stock | (F1) This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. |